Managing Adverse Effects Related to Newer Type 2 Diabetes Medications

Abstract

Get full access to this article

View all access options for this article.

References

Carpio

GRA

Fonseca

. Update on safety issues related to antihyperglycemic therapy. Diabetes Spectrum. 2014;27(2):92-100.

Brunton

. GLP-1 receptor agonists vs. DPP-4 inhibitors for type 2 diabetes. Is one approach more successful or preferable than the other? Int J Clin Pract. 2014;68:557-567.

Fujita

Inagaki

. Renal sodium glucose cotransporter 2 inhibitors as a novel therapeutic approach to treatment of type 2 diabetes: clinical data and mechanism of action. J Diabetes Investig. 2014;5(3):265-275.

Micromedex Solutions. http://www.micromedexsolutions.com/micromedex2/librarian/ND_T/evidencexpert/ND_PRevidencexpert/CS/165027/ND_AppProduct/evidencexpert/DUPLICATIONSHIELDSYNC/B56623/ND_PG/evidencexpert/ND_B/evidencexpert/ND_P/evidencexpert/PFActionId/pf.HomePage?navitem=topHome. Accessed May 13, 2015.

Food and Drug Administration. Briefing Material for April 14, 2015 Meeting of Endocrinologic and Metabolic Drugs Advisory Committee. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM442060.pdf. Accessed May 14, 2015.

O’Riordan

. TECOS: No CVD risks or heart failure with sitagliptin in high-risk diabetic patients. Medscape Medical news from the American Diabetes Association 75th Scientific Sessions. http://www.medscape.com/viewarticle/846075. Accessed July 28, 2015.

FDA Drug Safety Communication: FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood. http://www.fda.gov/Drugs/DrugSafety/ucm446845.htm. Accessed July 28, 2015.